136 related articles for article (PubMed ID: 34642090)
41. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.
Sugawara T; Ban D; Nishino J; Watanabe S; Maekawa A; Ishikawa Y; Akahoshi K; Ogawa K; Ono H; Kudo A; Tanaka S; Tanabe M
PLoS One; 2021; 16(4):e0249885. PubMed ID: 33844700
[TBL] [Abstract][Full Text] [Related]
42. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis.
Daamen LA; Groot VP; Besselink MG; Bosscha K; Busch OR; Cirkel GA; van Dam RM; Festen S; Groot Koerkamp B; Haj Mohammad N; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; Los M; Meijer GJ; de Meijer VE; Nieuwenhuijs VB; Pranger BK; Raicu MG; Schreinemakers JMJ; Stommel MWJ; Verdonk RC; Verkooijen HM; Molenaar IQ; van Santvoort HC;
Ann Surg; 2022 Apr; 275(4):769-775. PubMed ID: 32773631
[TBL] [Abstract][Full Text] [Related]
43. A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics.
Tian N; Wu D; Zhu L; Zeng M; Li J; Wang X
BMC Med Imaging; 2022 Jul; 22(1):116. PubMed ID: 35786426
[TBL] [Abstract][Full Text] [Related]
44. CT Radiomics-Based Preoperative Survival Prediction in Patients With Pancreatic Ductal Adenocarcinoma.
Park S; Sham JG; Kawamoto S; Blair AB; Rozich N; Fouladi DF; Shayesteh S; Hruban RH; He J; Wolfgang CL; Yuille AL; Fishman EK; Chu LC
AJR Am J Roentgenol; 2021 Nov; 217(5):1104-1112. PubMed ID: 34467768
[No Abstract] [Full Text] [Related]
45. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
46. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology.
Crippa S; Belfiori G; Bissolati M; Partelli S; Pagnanelli M; Tamburrino D; Gasparini G; Rubini C; Zamboni G; Falconi M
HPB (Oxford); 2021 Nov; 23(11):1666-1673. PubMed ID: 33934960
[TBL] [Abstract][Full Text] [Related]
47. Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Korrel M; Lof S; van Hilst J; Alseidi A; Boggi U; Busch OR; van Dieren S; Edwin B; Fuks D; Hackert T; Keck T; Khatkov I; Malleo G; Poves I; Sahakyan MA; Bassi C; Abu Hilal M; Besselink MG;
Ann Surg Oncol; 2021 Feb; 28(2):1079-1087. PubMed ID: 32583198
[TBL] [Abstract][Full Text] [Related]
48. Radiological prediction of portal vein infiltration in patients with pancreatic ductal adenocarcinoma.
Lapshyn H; Schulte T; Sondermann S; May K; Petrova E; Honselmann KC; Braun R; Zemskov S; Keck T; Wellner UF; Bausch D; Bolm L
Pancreatology; 2021 Jan; 21(1):155-162. PubMed ID: 33309623
[TBL] [Abstract][Full Text] [Related]
49. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer.
Crippa S; Guarneri G; Belfiori G; Partelli S; Pagnanelli M; Gasparini G; Balzano G; Lena MS; Rubini C; Doglioni C; Zamboni G; Falconi M
Eur J Surg Oncol; 2020 Aug; 46(8):1524-1531. PubMed ID: 32098733
[TBL] [Abstract][Full Text] [Related]
50. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study.
Zou S; Wang X; Chen H; Lin J; Wen C; Zhan Q; Chen H; Lu X; Deng X; Shen B
BMC Cancer; 2022 Jun; 22(1):649. PubMed ID: 35698045
[TBL] [Abstract][Full Text] [Related]
51. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
52. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; van Oosten AF; Molenaar IQ; Cameron JL; Weiss MJ; Yang SC; Wolfgang CL; He J
HPB (Oxford); 2019 Aug; 21(8):998-1008. PubMed ID: 30777697
[TBL] [Abstract][Full Text] [Related]
53. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
[TBL] [Abstract][Full Text] [Related]
54. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.
Nakano Y; Kitago M; Shinoda M; Abe Y; Yagi H; Hibi T; Takeuchi A; Aiura K; Itano O; Kitagawa Y
Cancer Med; 2017 Oct; 6(10):2278-2286. PubMed ID: 28925039
[TBL] [Abstract][Full Text] [Related]
55. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
56. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
57. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
58. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
Hosokawa Y; Nagakawa Y; Sahara Y; Takishita C; Katsumata K; Tsuchida A
Dig Surg; 2017; 34(2):125-132. PubMed ID: 27658221
[TBL] [Abstract][Full Text] [Related]
59. Time interval-based indication for liver resection of metastasis from pancreatic cancer.
Mitsuka Y; Yamazaki S; Yoshida N; Yan M; Higaki T; Takayama T
World J Surg Oncol; 2020 Nov; 18(1):294. PubMed ID: 33172482
[TBL] [Abstract][Full Text] [Related]
60. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
